Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:13:00.610Z.
Calculation as of: 2026-10-06T19:13:00.610Z.
Quote observation: 2026-10-06T19:07:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fae3dac89f6aae568c3e1e6131ec6a0b9ed594063ed7dd46d2bf25dadf8b5230
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
OKYO Pharma Limited
Market Cap
$56.02M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| OKYO Pharma Limited (OKYO) | $56.02M | N/A |
| Talphera, Inc. (TLPH)vs › | $57.09M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $58.21M | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $58.61M | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $53.93M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.62M | N/A |
| Spectral AI, Inc. (MDAI)vs › | $53.62M | N/A |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $53.55M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $59.64M | N/A |
| Aldeyra The (ALDX)vs › | $53.29M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
